KT Moortgat brings experience in venture capital and startup leadership to her current role at AbbVie Ventures, where she is expanding the corporate venture group’s investment portfolio and presence on the US west coast. Since joining AbbVie in 2017, she has driven multiple new investments at seed, Series A and Series B stages; and supported therapeutic company formation, financing, and growth. Board representation: PACT Pharma, Nitrome Biosciences, ESCAPE Bio, eFFECTOR Therapeutics, Stemson Therapeutics, and Tizona Therapeutics.
Previously, KT was CEO of a clinical-stage company, through the funding and launch of efficacy study for a microbiome therapy. She has held executive and consulting roles in a number of venture-backed and public life science companies. Prior, KT was a partner at the venture capital firm Mohr Davidow Ventures, with a focus on deep technology opportunities in life science and energy. She also founded the hub of entrepreneurship at QB3 and the University of California San Francisco.
She held a Sloan Postdoctoral Fellowship at UC San Francisco, and earned a PhD at UC San Diego and the Salk Institute as a NIH Predoctoral Fellow. She graduated with a BA from UC Berkeley.
Previously, KT was CEO of a clinical-stage company, through the funding and launch of efficacy study for a microbiome therapy. She has held executive and consulting roles in a number of venture-backed and public life science companies. Prior, KT was a partner at the venture capital firm Mohr Davidow Ventures, with a focus on deep technology opportunities in life science and energy. She also founded the hub of entrepreneurship at QB3 and the University of California San Francisco.
She held a Sloan Postdoctoral Fellowship at UC San Francisco, and earned a PhD at UC San Diego and the Salk Institute as a NIH Predoctoral Fellow. She graduated with a BA from UC Berkeley.
Speaking In
1:00 PM - 2:00 PM (PDT)
Tuesday, October 13
As the furthest developed new Alzheimer’s therapy candidate approaches a regulatory review decision…